Cisco, Chang & Charlie

by DrKSSMDPhD | May 16, 2015 3:46 pm


Notice: Undefined variable: supress_subtitle in /home/sgumdev/public_html/wp-content/themes/sgum_2016/wpf.php on line 42

First of Two Parts

This is premium content. To view this article (and to have full access to the rest of our articles), sign up. Already a member? Log in.

Source URL: https://sgumdev.stockgumshoe.com/2015/05/cisco-chang-charlie/


1.2K Comments
Inline Feedbacks
View all comments
sma43
sma43
5 years ago

Dear Dr KSS – Some time ago (May 2015), you wrote a damning critique of Corbus Pharmaceuticals (CRBP), implying its CEO Yuval Cohen, PhD is a “huckstermeister” and declaring, among other things:

“[regarding CRBP’s drug Resunab for CF] Corbus Pharmaceuticals is lost, my Gummerati colleagues, and desperately needs guidance. It has set sail on a foolโ€™s errand, one with absolutely no chance of clinical success. $CRBP is in no way appropriate for investment here.”

and

“I cannot envisage Resumab (sic) as having a snowballโ€™s chance in hell helping scleroderma, a devastating and often aggressive disease.”

You even didn’t like the name of the drug (Resunab) or the location of the HQ (Norwood, MA, a suburb of Boston).

I was a fairly new life member of Gumshoe at that point, and was a little surprised at how negative you were. I also wasn’t sure you had really looked very deep into the information available about Corbus, as opposed to your background info and experience in the existing treatments for CF, but I’m not an MD, PhD (or genius) so I didn’t really have a basis to question your opinions.

In the meantime, Corbus has now completed its Phase II trial of Resunab in Systemic Sclerosis (https://finance.yahoo.com/news/corbus-pharmaceuticals-announces-completion-phase-113000775.html) and will be announcing top line data this quarter. Resunab was granted Orphan Drug Designation and Fast Track status for the treatment of systemic sclerosis by the U.S. Food and Drug Administration (“FDA”) in 2015. Corbus received approval for an open-label extension to its Phase 2 clinical study of Resunab for systemic sclerosis from the FDA in April of 2016. I can’t help thinking that your earlier analysis confused an inflammation response with an immune response. CRBP’s claim is that “In effect, Resunab triggers endogenous pathways to turn “off” chronic inflammation and fibrotic processes, without causing immunosuppression.”

Insiders and institutions have been loading up on the shares, and average daily volume has increased to over 1,000,000 shares as compared to the 80,000 shares when you wrote your piece.

I continue to hold my shares of CRBP, which I purchased for $1.00, and are now selling for $9.00 (recently as high as $10.80). Cantor Fitzgerald just initiated coverage of CRBP with a target of $17. I know this is only paper profit at this point, but it goes well against my paper losses in FLKS and ZFGN.

I’m just wondering if it might be a good time to take another look at Corbus based on currently available information, or if you would just prefer to wait and see the results of the several clinical trials (including CF) that will soon be reported (but after which the potential upside may be smaller). Thank you.

Add a Topic
3932
Add a Topic
3022
Add a Topic
3022
๐Ÿ‘ 3
๐Ÿ‘ 47658
Walsh
Walsh
5 years ago
Reply to  DrKSSMDPhD

“So donโ€™t try going all esoteric on me and reciting passages from the Kabbalah and claiming that Corbus is onto some mysterious theta-wave higher order of consciousness magic carpet by which it can nix fibrosis and not molest inflammation.”
Best sentence of the year. Literally laughed out loud.

Add a Topic
5554
๐Ÿ‘ 1865
arch1
5 years ago
Reply to  DrKSSMDPhD

Dr KSS Doncha know that true believers in ethereal and wondrous fairy dust and moonbeams of the Cannabis will find magic elixer in every manifestation?
If told cannabinoid receptor whiz CB-2 cured rectal itch, eyelid flutter and venereal warts they would happily rotate the swabbing of all from the sacred chalice. ๐Ÿ™‚

Add a Topic
3932
๐Ÿ‘ 7795
sma43
sma43
5 years ago
Reply to  DrKSSMDPhD

OK, I’ll take that as a “no.” Thanks.

๐Ÿ‘ 3
Lynn Clark, Stock Gumshoe
Admin

This thread has been closed. The discussion has moved over to Dr. KSS’s latest article, which can be found on his Stock Gumshoe page.

Add a Topic
5971
๐Ÿ‘ 151
Lynn Clark, Stock Gumshoe
Admin

This discussion thread has been closed. The conversation has moved over to Dr. KSS’s latest article, which will be at the top of his Stock Gumshoe page.

๐Ÿ‘ 151
1 17 18 19